Research and Development Laboratory, Greer Laboratories, Inc., Lenoir, North Carolina 28645, USA.
Ann Allergy Asthma Immunol. 2012 Mar;108(3):201-5. doi: 10.1016/j.anai.2012.01.011.
Immunotherapy dose recommendations for allergens specified in practice parameter updates have varied from version to version, and no convenient methods are available to incorporate dose changes or targets into maintenance vial formulations for patients.
To compare the allergen immunotherapy dose recommendations published between 2003-2011, and to provide math-free dosing tables that translate dose targets for single or multiple extracts into maintenance vial compositions.
Dose recommendations obtained from immunotherapy practice parameters published in 2003, 2007 and 2011, plus a worksheet created in 2004, were tabulated and compared. Conversion tables were created based on the fixed mathematical relationships between extract concentrate strengths and maintenance immunotherapy dose targets. Considerations of stock mixes, glycerin levels, and allergen compatibilities were applied using two examples of common extract formulations.
Changes to immunotherapy dose ranges for standardized extracts included adjustment of upper limits (short ragweed), lower limits (pasture grasses), or both (cat, dust mites, Bermuda grass). Dose ranges for non-standardized products have also been modified over time. Conversion tables specified the extract concentrate volumes or percentages required to deliver minimum, midrange and maximum recommended doses with 0.5 mL injection volumes.
These dosing guides, used in conjunction with cross-reactivity, compatibility and glycerin tolerance information, provide clinicians with a convenient and systematic method for determining the numbers and strengths of extracts that can be combined into treatment vials at various dose levels, and can facilitate optimization of maintenance immunotherapy mixtures for patients exhibiting a wide range of allergen sensitivities and specificities.
实践参数更新中指定的过敏原免疫疗法剂量建议在各版本之间存在差异,而且目前尚无便捷的方法可将剂量变化或目标纳入患者的维持小瓶制剂中。
比较 2003-2011 年间发表的过敏原免疫疗法剂量建议,并提供无需计算的剂量表,可将单种或多种提取物的剂量目标转换为维持小瓶制剂的成分。
汇总并比较了 2003、2007 和 2011 年发表的免疫疗法实践参数中的剂量建议,以及 2004 年创建的工作表。根据提取物浓缩物强度与维持免疫疗法剂量目标之间的固定数学关系创建转换表。使用两种常见提取物配方的示例,考虑了库存混合物、甘油水平和过敏原相容性等因素。
标准化提取物的免疫疗法剂量范围变化包括调整上限(豚草)、下限(牧草)或两者(猫、尘螨、百慕大草)。非标准化产品的剂量范围也随时间而改变。转换表指定了以 0.5 毫升注射体积输送最小、中值和最大推荐剂量所需的提取物浓缩物体积或百分比。
这些剂量指南与交叉反应性、相容性和甘油耐受性信息一起使用,为临床医生提供了一种便捷且系统的方法,可确定可组合到各种剂量水平的治疗小瓶中的提取物数量和强度,还可以促进优化对表现出广泛过敏原敏感性和特异性的患者的维持免疫疗法混合物。